Бендамустин: новый взгляд на лечение хронического лимфоцитарного лейкоза
Аннотация
Хронический лимфолейкоз (ХЛЛ) – самый частый вид лейкозов у взрослых. Несмотря на значительные достижения в терапии этого заболевания у молодых пациентов, лечение пожилых больных представляет большую проблему, прежде всего из-за неудовлетворительной переносимости режимов, содержащих пуриновые аналоги. В 2010 г. в России зарегистрирован новый препарат рибомустин, сочетающий в себе свойства алкилирующих соединений и аналогов пуринов. Большое преимущество рибомустина состоит в его низкой токсичности. В нескольких исследованиях показано, что рибомустин эффективен как в ситуации рецидива, так и в терапии 1-й линии больных ХЛЛ. В данном обзоре рассматриваются результаты клинических испытаний рибомустина у больных ХЛЛ.
Об авторе
Е. А. Никитин
РАМН
Россия
Россия
Евгений Александрович Никитин
Гематологический научный центр
Москва
Список литературы
1. American Cancer Society [Web site]. Cancer Facts & Figures 2008. Atlanta: American Cancer Society. Available at: https://www.cancer.org/downloads/stt/2008cafffinalsecured.pdf.%20accessed:%20november%201,%202008. Accessed: November 1, 2008.
2. National Comprehensive Cancer Network [Web site]. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphomas. Version 3. 2008. Available at: https://pubmed.ncbi.nlm.nih.gov/20202462/. Accessed: November 1, 2008.
3. Hallek M. Chronic lymphocytic leukemia (CLL): first-line treatment. Hematology Am Soc Hematol Educ Program 2005: 285–99.
4. Keating M. J., O'Brien S., Albitar M. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–88.
5. National Cancer Institute [Web site]. SEER Cancer Statistics Review, 1975–2002, National Cancer Institute. Bethesda, MD. Based on November 2004 SEER data submission, posted to the SEER Web site 2005. Available at: http://seer.cancer.gov/csr/1975_2002/. Accessed: November 1, 2008.
6. Eichhorst B. F., Busch R., Stilgenbauer S. et.al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009 Oct 15;114 (16): 3382–91.
7. Wierda W. G., Kipps T. J., Keating M. J. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 6325–32.
8. Keating M. J., O'Brien S., Kontoyiannis D. et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755–62.
9. Nabhan C., Shanafelt T. D., Kay N. E. Controversies in the front-line management of chronic lymphocytic leukemia. Leuk Res 2008; 32: 679–88.
10. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002; 29: 4–11.
11. Aivado M., Schulte K., Henze L. et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002; 29: 19–22.
12. Bergmann M. A., Goebeler M. E., Herold M. et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005; 90: 1357–64.
13. Fischer K., Stilgenbauer S., Schweighofer C. D. et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2007; 110: 913A (Abstract 3106).
14. Kath R., Blumenstengel K., Fricke H. J. et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001; 127: 48–54.
15. Lissitchkov T., Arnaudov G., Peytchev D. et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006; 132: 99–104.
16. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002; 128: 603–9.
17. Heider A., Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001; 12: 725–9.
18. Herold M., Schulze A., Niederwieser D. et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132: 105–12.
19. Koenigsmann M., Knauf W., Herold M. et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004; 45: 1821–7.
20. Rummel M. J., Al-Batran S. E., Kim S. Z. et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383–9.
21. Knop S., Straka C., Haen M. et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90: 1287–8.
22. Ponisch W., Mitrou P. S., Merkle K. et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205–12.
23. Strumberg D., Harstrick A., Doll K. et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7: 415–21.
24. Hartmann M., Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972; 287: 386–9.
25. Leoni L. M., Bailey B., Reifert J. et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309–17.
26. Owen J. S., Melhem M., D'Andrea D. et al. Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin lymphoma. Pharmacol Ther 2008; 83 (Suppl 1): 54.
27. Teichert J., Baumann F., Chao Q. et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59: 759–70.
28. Schwanen C., Hecker T., Hubinger G. et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002; 16: 2096–105.
29. Konstantinov S. M., Kostovski A., Topashka-Ancheva M. et al. Cytotoxic efficacy of bendamustine in human Leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002; 128: 271–8.
30. Chow K. U., Boehrer S., Geduldig K. et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001; 86: 485–93.
31. Gaul L., Mandl-Weber S., Baumann P. et al. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATMp53- p21-pathways. J Cancer Res Clin Oncol 2008; 134: 245–53.
32. Leoni L. M., Bailey B., Niemeyer C. C. et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Amer Assoc Cancer Res 2004; 45: 1215.
33. Chow K. U., Sommerlad W. D., Boehrer S. et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87: 33–43.
34. Rummel M. J., Chow K. U., Hoelzer D. et al. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 2002; 29 (4 Suppl 13): 12–4.
35. Niederle N., Balleisen L., Heit W. et al. Bendamustin vs fludarabine as second line treatment for patients with chronic lymphocytic leukemia – first interim results of a randomized study. Ann Oncol;19 (Suppl 4), iv194 (2008) (Abstract 379).
36. Knauf W., Lissitchkov T., Aldoud A. et al. Bendamustine versus chlorambucil in treatment-nave patients with B-cell chronic lymphocytic Leukemia (BCLL): results of an international phase III study J Clin Oncol 2009; Vol 27; N26: 4378–84.
37. Koppler H., Heymanns J., Pandorf A. et al. Bendamustine plus mitoxantrone – a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 2004; 45: 911–3.
38. Weide R., Pandorf A., Heymanns J. et al. Bendamustine / mitoxantrone / rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004; 45: 2445–9.
39. Treanda® (bendamustine hydrochloride) for Injection [prescribing information]. Frazer, PA: Cephalon, Inc; 2008.
40. Инструкция по медицинскому применению препарата рибомустин.
Рецензия
Для цитирования:
Никитин Е.А. Бендамустин: новый взгляд на лечение хронического лимфоцитарного лейкоза. Онкогематология. 2010;(3):46-51.
For citation:
Nikitin Ye.A. Bendamustine: a new view on treatment of chronic lymphocytic leukemia. Oncohematology. 2010;(3):46-51. (In Russ.)
Просмотров:
381
Послать статью по эл. почте 